MDMA (Ecstasy) produces a unique altered state of consciousness called the entactogenic syndrome, described as an open mind state, which may have therapeutic applications in psychotherapy and neuropsychiatric disorders. The pharmacological mechanism involves disruption of monoaminergic neurotransmission, but its full mechanism is not completely understood. Despite many structurally similar molecules, almost no experimental evidence shows that any analogue truly reproduces MDMA's full pharmacological profile, suggesting MDMA may be a pharmacological rarity. This review summarizes MDMA's pharmacology and the evidence from classical MDMA analogues, highlighting the need to develop better analogues.
In rats, MDMA (ecstasy) impairs both short-term and long-term visuospatial memory while increasing long-term potentiation (LTP) in the prefrontal cortex. Its brominated analog, 2Br-4,5-MDMA, preserves long-term visuospatial memory and slightly accelerates short-term memory compared to controls, yet also increases LTP similarly to MDMA. These findings suggest that aromatic bromination of the MDMA molecule, which eliminates typical entactogenic-like effects, also modifies effects on higher cognitive functions like visuospatial learning. The cognitive changes do not appear linked to the increase in prefrontal cortex LTP.